BC Week In Review | Apr 15, 2013
Company News

Penederm, SmithKline deal

The companies will co-develop an over-the-counter product using DERM's TopiCare polymer delivery compounds with an undisclosed SmithKline Beecham formulation. SmithKline will have the exclusive option to market the product worldwide and will be liable for...
BC Week In Review | Apr 15, 2013
Company News

Penederm sales and marketing update

DERM began U.S. sales of its Avita cream, a topical form of retinoic acid to treat acne. Product stocking to wholesalers will be completed by the third quarter. DERM's contract sales force will market the...
BC Week In Review | Apr 15, 2013
Clinical News

Penederm regulatory update

DERM received U.K. marketing approval for Avita, retinoic acid cream and gel formulations used to treat acne. The U.K. will serve as a sponsor to help DERM gain approval in other European countries. DERM plans...
BC Week In Review | Apr 15, 2013
Company News

Penederm board of directors update

Penederm Inc. (DERM), Foster City, Calif.   Business: Dermatology, Drug delivery   Appointed: Director David Collins, to chairman  ...
BC Week In Review | Apr 15, 2013
Clinical News

Penederm regulatory update

The FDA approved Mentax , DERM's 1 percent butenafine HC1 cream, to treat tinea corporis (ringworm) and tinea cruris (groin fungus). The agency approved the product in October 1996 to treat interdigital tinea pedis (athlete's foot)....
BC Week In Review | Oct 12, 1998
Company News

Penederm, Mylan Laboratories Inc. deal

Mylan completed its acquisition of DERM (see BioCentury, June 29). Penederm Inc. (DERM), Foster City, Calif.   Mylan Laboratories Inc., Pittsburgh, Penn.   Business: Dermatology, Drug delivery  ...
BC Week In Review | Jul 27, 1998
Company News

Penederm, Pedinol Pharmacal Inc. sales and marketing update

The companies will co-promote DERM's Mentax topical antifungal product to podiatrists in the U.S. Penederm Inc. (DERM), Foster City, Calif.   Pedinol Pharmacal Inc., Pharmingdale, N.Y.   Business: Dermatology  ...
BC Week In Review | Jul 13, 1998
Company News

Mylan Laboratories Inc., Penederm sales and marketing update

MYL's Bertek Pharmaceuticals Inc. subsidiary (Sugar Land, Texas) will co-promote DERM's Avita, a topical retinoic acid product to treat acne. The agreement provides an upfront license fee and prepaid co-promotion payments to DERM totaling from...
BC Week In Review | Jun 29, 1998
Company News

Penederm, Mylan Laboratories Inc. deal

Mylan, a developer of generic pharmaceuticals delivered orally and via transdermal patches, will acquire DERM in a stock deal worth $205 million based on Mylan's closing price prior to the announcement. Mylan will issue 0.68...
BioCentury | Jun 29, 1998
Strategy

Get a product - get acquired

With the exception of Baxter International Inc. 's purchase of Somatogen Inc. in February, pharmaceutical company acquisitions of product-oriented biotechs this year have been limited mostly to those biotech companies with products on the market....
Items per page:
1 - 10 of 61
BC Week In Review | Apr 15, 2013
Company News

Penederm, SmithKline deal

The companies will co-develop an over-the-counter product using DERM's TopiCare polymer delivery compounds with an undisclosed SmithKline Beecham formulation. SmithKline will have the exclusive option to market the product worldwide and will be liable for...
BC Week In Review | Apr 15, 2013
Company News

Penederm sales and marketing update

DERM began U.S. sales of its Avita cream, a topical form of retinoic acid to treat acne. Product stocking to wholesalers will be completed by the third quarter. DERM's contract sales force will market the...
BC Week In Review | Apr 15, 2013
Clinical News

Penederm regulatory update

DERM received U.K. marketing approval for Avita, retinoic acid cream and gel formulations used to treat acne. The U.K. will serve as a sponsor to help DERM gain approval in other European countries. DERM plans...
BC Week In Review | Apr 15, 2013
Company News

Penederm board of directors update

Penederm Inc. (DERM), Foster City, Calif.   Business: Dermatology, Drug delivery   Appointed: Director David Collins, to chairman  ...
BC Week In Review | Apr 15, 2013
Clinical News

Penederm regulatory update

The FDA approved Mentax , DERM's 1 percent butenafine HC1 cream, to treat tinea corporis (ringworm) and tinea cruris (groin fungus). The agency approved the product in October 1996 to treat interdigital tinea pedis (athlete's foot)....
BC Week In Review | Oct 12, 1998
Company News

Penederm, Mylan Laboratories Inc. deal

Mylan completed its acquisition of DERM (see BioCentury, June 29). Penederm Inc. (DERM), Foster City, Calif.   Mylan Laboratories Inc., Pittsburgh, Penn.   Business: Dermatology, Drug delivery  ...
BC Week In Review | Jul 27, 1998
Company News

Penederm, Pedinol Pharmacal Inc. sales and marketing update

The companies will co-promote DERM's Mentax topical antifungal product to podiatrists in the U.S. Penederm Inc. (DERM), Foster City, Calif.   Pedinol Pharmacal Inc., Pharmingdale, N.Y.   Business: Dermatology  ...
BC Week In Review | Jul 13, 1998
Company News

Mylan Laboratories Inc., Penederm sales and marketing update

MYL's Bertek Pharmaceuticals Inc. subsidiary (Sugar Land, Texas) will co-promote DERM's Avita, a topical retinoic acid product to treat acne. The agreement provides an upfront license fee and prepaid co-promotion payments to DERM totaling from...
BC Week In Review | Jun 29, 1998
Company News

Penederm, Mylan Laboratories Inc. deal

Mylan, a developer of generic pharmaceuticals delivered orally and via transdermal patches, will acquire DERM in a stock deal worth $205 million based on Mylan's closing price prior to the announcement. Mylan will issue 0.68...
BioCentury | Jun 29, 1998
Strategy

Get a product - get acquired

With the exception of Baxter International Inc. 's purchase of Somatogen Inc. in February, pharmaceutical company acquisitions of product-oriented biotechs this year have been limited mostly to those biotech companies with products on the market....
Items per page:
1 - 10 of 61